TRENDS OF UTILIZATION OF AND SPENDING ON ANTI-TUBERCULOSIS MEDICATIONS IN THE UNITED STATES MEDICAID PROGRAM FROM 1991 TO 2011

Author(s)

Alahmari AK*1;Aldawsari MF1;Luder HR1;Wigle PR1;Kelton CM2, Guo JJ1 1University of Cincinnati College of Pharmacy, Cincinnati, OH, USA, 2University of Cincinnati College of Business, Cincinnati, OH, USA

OBJECTIVES: Tuberculosis (TB) is a serious infectious disease which affects the respiratory system. In 2011, 10,521 new TB cases were reported in the U.S. The anti-TB drug class contains both first- and second-line treatments, with the first-line regimen considered the skeleton of TB eradication. The purpose of the current study was to describe the trends in utilization of and spending on anti-TB drugs generally and individual anti-TB medications in the U.S. Medicaid Program. METHODS: A retrospective, descriptive analysis was conducted to examine the trends in utilization of and spending on anti-TB medications, using the national Medicaid pharmacy files from 1991 quarter 1 through 2011 quarter 2. Study drugs included isoniazid, rifampin, pyrazinamide, and ethambutol (first-line therapies); and cycloserine, kanamycin, streptomycin, amikacin, capreomycin, moxifloxacin, rifater, rifamate, thioamides, paser, rifapentine and rifabutin (second-line therapies).  Quarterly prescription numbers and reimbursement amounts were calculated over time by summing data for individual drug products. The quarterly per-prescription reimbursement as a proxy for drug price was computed for each drug. RESULTS: Total Medicaid utilization of anti-TB drugs rose by 43% from 151,344 in 1991 to 216,271 in 2011. Utilization of the first-line drugs increased from 47,348 in 1991 to 65,482 in 1993, stayed at this level for 4 years, and then decreased to an average of 43,245 per year. Medicaid reimbursement for anti-TB medications increased 246% ($6.5 million to $22.4 million) between 1991 and 2011.  Prices for second-line drugs were higher than those for traditional drugs due to absence of generic availability for the newer drugs. In 2011, reimbursement for second-line agents was 10 times that for first-line therapies. CONCLUSIONS: Utilization of anti-TB drugs was closely related to disease incidence. The rise in spending on second-line agents may be due to increased usage for other indications along with rising prices. An effective management program for anti-TB drug prescribing might be helpful for Medicaid.

Conference/Value in Health Info

2013-05, ISPOR 2013, New Orleans, LA, USA

Value in Health, Vol. 16, No. 3 (May 2013)

Code

PRS60

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×